Shenzhen New Industries Biomedical Engineering (300832) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 reached ¥1,124.76 million, up 10.12% year-over-year, with overseas business growing 27.03% and domestic business nearly flat at 0.11%.

• Net profit attributable to shareholders was ¥437.51 million, a 2.65% increase year-over-year.

• Large equipment installations accelerated, with 303 MAGLUMI X8 analyzers and 39 SATLARS T8 lines sold/installed.

• Cash flow from operations dropped sharply due to ERP system upgrade and delayed payments.

Financial highlights

• Operating income: ¥1,124.76 million, up 10.12% year-over-year.

• Net profit: ¥437.51 million, up 2.65% year-over-year.

• Basic and diluted EPS: ¥0.5568, up 2.64% year-over-year.

• Gross margin: 68.0% (calculated from reported revenue and cost of sales).

• Cash flow from operations: ¥18.54 million, down 92.92% year-over-year.

Outlook and guidance

• Domestic market faces pressure from centralized procurement policies, while overseas business is expected to maintain steady growth.